Log in

NASDAQ:MNOV - MediciNova Stock Price, Forecast & News

$7.98
+0.16 (+2.04 %)
(As of 12/8/2019 03:44 AM ET)
Today's Range
$7.79
Now: $7.99
$8.03
50-Day Range
$7.00
MA: $7.71
$8.72
52-Week Range
$6.68
Now: $7.99
$13.37
Volume89,005 shs
Average Volume95,625 shs
Market Capitalization$350.08 million
P/E RatioN/A
Dividend YieldN/A
Beta1.2
MediciNova, Inc, a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:MNOV
CUSIPN/A
Phone858-373-1500

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$1.75 per share

Profitability

Net Income$-14,670,000.00

Miscellaneous

Employees9
Market Cap$350.08 million
Next Earnings Date2/12/2020 (Estimated)
OptionableOptionable

Receive MNOV News and Ratings via Email

Sign-up to receive the latest news and ratings for MNOV and its competitors with MarketBeat's FREE daily newsletter.


MediciNova (NASDAQ:MNOV) Frequently Asked Questions

What is MediciNova's stock symbol?

MediciNova trades on the NASDAQ under the ticker symbol "MNOV."

How were MediciNova's earnings last quarter?

MediciNova, Inc. (NASDAQ:MNOV) issued its earnings results on Friday, October, 25th. The biopharmaceutical company reported ($0.05) earnings per share for the quarter, beating analysts' consensus estimates of ($0.15) by $0.10. View MediciNova's Earnings History.

When is MediciNova's next earnings date?

MediciNova is scheduled to release their next quarterly earnings announcement on Wednesday, February 12th 2020. View Earnings Estimates for MediciNova.

What price target have analysts set for MNOV?

1 equities research analysts have issued 1-year target prices for MediciNova's stock. Their forecasts range from $22.00 to $22.00. On average, they expect MediciNova's share price to reach $22.00 in the next twelve months. This suggests a possible upside of 175.5% from the stock's current price. View Analyst Price Targets for MediciNova.

What is the consensus analysts' recommendation for MediciNova?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MediciNova in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for MediciNova.

Has MediciNova been receiving favorable news coverage?

Media headlines about MNOV stock have trended somewhat positive this week, InfoTrie reports. The research group scores the sentiment of media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. MediciNova earned a news sentiment score of 2.0 on InfoTrie's scale. They also gave news stories about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View News Stories for MediciNova.

Who are some of MediciNova's key competitors?

What other stocks do shareholders of MediciNova own?

Who are MediciNova's key executives?

MediciNova's management team includes the folowing people:
  • Dr. Yuichi Iwaki, Co-Founder, Pres, CEO & Exec. Director (Age 69)
  • Mr. Masatsune Okajima, Head of Japanese Office & VP (Age 51)
  • Dr. Kazuko Matsuda M.P.H., M.D., Ph.D., MPH, Chief Medical Officer (Age 53)
  • Ms. Carla Reyes, Chief Financial Officer (Age 47)
  • Mr. John O'Neil CPA, Controller

Who are MediciNova's major shareholders?

MediciNova's stock is owned by a variety of of institutional and retail investors. Top institutional investors include State Street Corp (1.69%), Alps Advisors Inc. (0.20%), California Public Employees Retirement System (0.13%), Squarepoint Ops LLC (0.07%), Barclays PLC (0.05%) and Tower Research Capital LLC TRC (0.01%). View Institutional Ownership Trends for MediciNova.

Which major investors are selling MediciNova stock?

MNOV stock was sold by a variety of institutional investors in the last quarter, including Barclays PLC, Alps Advisors Inc. and Tower Research Capital LLC TRC. View Insider Buying and Selling for MediciNova.

Which major investors are buying MediciNova stock?

MNOV stock was purchased by a variety of institutional investors in the last quarter, including State Street Corp, Squarepoint Ops LLC and California Public Employees Retirement System. View Insider Buying and Selling for MediciNova.

How do I buy shares of MediciNova?

Shares of MNOV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is MediciNova's stock price today?

One share of MNOV stock can currently be purchased for approximately $7.99.

How big of a company is MediciNova?

MediciNova has a market capitalization of $350.08 million. The biopharmaceutical company earns $-14,670,000.00 in net income (profit) each year or ($0.36) on an earnings per share basis. MediciNova employs 9 workers across the globe.View Additional Information About MediciNova.

What is MediciNova's official website?

The official website for MediciNova is http://medicinova.com/.

How can I contact MediciNova?

MediciNova's mailing address is 4275 EXECUTIVE SQUARE SUITE 300, LA JOLLA CA, 92037. The biopharmaceutical company can be reached via phone at 858-373-1500 or via email at [email protected]


MarketBeat Community Rating for MediciNova (NASDAQ MNOV)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  180 (Vote Outperform)
Underperform Votes:  150 (Vote Underperform)
Total Votes:  330
MarketBeat's community ratings are surveys of what our community members think about MediciNova and other stocks. Vote "Outperform" if you believe MNOV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MNOV will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/8/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel